SCY 635

Drug Profile

SCY 635

Alternative Names: SCY-635

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SCYNEXIS
  • Class Antivirals; Ciclosporins
  • Mechanism of Action Cyclophilin inhibitors; Hepatitis B virus replication inhibitors; Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C
  • No development reported Hepatitis B

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in USA (PO)
  • 03 Nov 2014 SCY 635 licensed to Waterstone Pharmaceuticals worldwide
  • 25 Apr 2013 Final pharmacodynamics data from preclinical studies presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL-2013),,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top